Skip to content
← Full study record

NCT03046953 · MORE INFO

Limitations, agreements, and source contact

Avelumab in Relapsed and Refractory Peripheral T-cell Lymphoma · Source last updated 2024-07-16

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement
pi Sponsor Employee
false
restrictive Agreement
false
limitations And Caveats
description
For one of the secondary outcomes- the maximum percentage change in the sum of the products of diameters, calculated from measurements of target tumour masses assessed by CT scans- no reliable conclusions could be drawn from this analysis due to missing data and a lack of consistent reporting.
point Of Contact
email
avail-t@trials.bham.ac.uk
organization
CRCTU Birmingham
phone
+44 121 371 7862
title
C Morland Cinical Trial Coordinator
Complete source fields
certain Agreement
pi Sponsor Employee
false
restrictive Agreement
false
limitations And Caveats
description
For one of the secondary outcomes- the maximum percentage change in the sum of the products of diameters, calculated from measurements of target tumour masses assessed by CT scans- no reliable conclusions could be drawn from this analysis due to missing data and a lack of consistent reporting.
point Of Contact
email
avail-t@trials.bham.ac.uk
organization
CRCTU Birmingham
phone
+44 121 371 7862
title
C Morland Cinical Trial Coordinator

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice